Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P. Aug 14, 2026 06:09AM
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P. May 15, 2026 06:39AM
Form SCHEDULE 13G Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P. Feb 17, 2026 06:28AM
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting Nov 6, 2025 07:03AM
Opus Genetics raises $23 million in registered direct offering Nov 6, 2025 07:01AM


Nov 6, 2025 07:00AM Opus Genetics Announces $23 Million Registered Direct Offering
Nov 6, 2025 07:00AM Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease